Health
Virus drug benefit only marginal: study – Education – Australian Associated Press
Researchers say a new study of Gilead Sciences’ remdesivir raises questions about the efficacy of the drug in the treatment of COVID-19.
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly shorten hospital stays and a 10-day course did not show a benefit, according to new data.
The drug, which was shown in a trial of severely ill COVID-19 patients to shorten their hospital recovery time, has been at the forefront of the battle against the pandemic.
The 600-patient analysis, published on Friday by the Journal of the American Medi…
-
General8 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News18 hours agoRainbow Beach surfer’s untold 7/7 story
-
Noosa News10 hours agoWoman left with significant arm injuries in lion attack at Darling Downs Zoo in Queensland
-
General23 hours agoWest Indies vs Australia live: Second Test, day three from Grenada